Concert Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapeutics using its proprietary deuterium-modified drug development platform (DCE Platform); the platform enhances properties such as clinical safety, tolerability, and efficacy of existing drugs through strategic deuterium substitution. Founded in 2006 and headquartered in Lexington, Massachusetts, the company focuses on autoimmune diseases, with its lead product candidate deuruxolitinib (Leqselvi, formerly CTP-543), a once-daily oral JAK1/JAK2 inhibitor, approved by the U.S. FDA in July 2024 for adults with severe alopecia areata and commercially launched in the U.S. in 2025. Previously advanced through Phase 3 THRIVE-AA trials for alopecia areata, deuruxolitinib demonstrated significant scalp hair coverage improvements; earlier pipeline efforts targeted cystic fibrosis with candidates like CTP-656 and other deuterium-modified compounds across immunology, neurology, and oncology. Sun Pharmaceutical Industries Ltd. completed its acquisition of Concert Pharmaceuticals in March 2023 for $576 million, positioning Concert as a wholly-owned subsidiary and enabling Sun Pharma to advance and commercialize deuruxolitinib globally while strengthening its dermatology portfolio. Operations remain centered in the U.S., with products directed at patients with serious autoimmune dermatological conditions and potential expansion into additional therapeutic areas leveraging the DCE Platform.
Concert Pharmaceuticals: Negative Spread But Interesting CVR
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
Why Concert Pharmaceuticals Stock Rocketed Higher This Week
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE
SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Concert Pharmaceuticals, Inc. Buyout
Shareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun Pharma
CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference